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and culprit vessel angiography and intervention during transradial primary PCI is
feasible. The aim of this study is to investigate the feasibility of using a single guiding
catheter (MAC 3.5) for left and right coronary angiography and intervention in pa-
tients with STEMI.
Methods: This was a single-center, prospective, randomized study conducted
from August 2011 to April 2012, 150 patients with STEMI indicated for
transradial primary PCI performed by two experienced transradial operators were
randomized into two groups : MAC group (75 cases) consisted of patients who
underwent coronary angiography and primary PCI by using a single guiding
catheter (MAC3.5). Control group (75 cases) included patients who ﬁrst under-
went coronary angiography with Tiger diagnostic catheter followed by guiding
catheter selection at the operator’s discretion for intervention. The primary out-
comes were cathlab door to balloon time (C2B) and ﬂuoroscopy time. The
secondary outcomes were composite of all-cause death, myocardial infarction or
non-coronary artery bypass graft (non-CABG) -related major bleeding at 30 days
and 2 year.
Results: Baseline patient characteristics were similar between the MAC group and
control group. the sheath placement time (1.84 1.41 min vs 1.620.88 min), the PCI
procedural success rate (88.9% vs 85.9%) and contrast consumption (12629 ml vs
12833 ml) in the two groups were not statistically signiﬁcant (P>0.05). Compare
with the Control group ,C2B time, total procedure time and the overall ﬂuoroscopy
time were signiﬁcantly lower in MAC Group (16.104.49 min vs 18.64 4.20 min ,
P ¼0.001; 29.818.06 min vs 35.7712.01 min, P ¼0.001; 8.40 2.71min vs 10.05
4.90 min, P<0.05, respectively). The secondary endpoints at 30 days was 5 (6.6%)
of 75 patients in the MAC group compared with 4 (5.3%) of 75 in the Control group
(HR 0$98, 95% CI 0.25-3.94; P¼0$98). There is no difference of two-year event-free
survival in the two group (86.7% vs 88%, hazard ratio 0.654, 95% CI 0.28-1.53
P¼0.327), respectively.
Conclusions: A single transradial MAC3.5 guiding catheter for coronary angiography
and intervention seems to be a better option for patients with STEMI for whom pri-
mary PCI is planned. It can shorten C2B time, procedure time and ﬂuoroscopy time.
Further study is required to determine whether this strategy can favorably affect
clinical outcomes.GW25-e4500
Tailored anti-platelet treatment guided by the platelet function assays reduces
the major cardiac events in patients undergoing percutaneous coronary
intervention: a meta- analysis of randomized controlled trials
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Objectives: To investigate whether the tailored anti-platelet treatments (TAT) guided
by the platelet function assays improve clinical outcome in patients undergoing
percutaneous coronary intervention (PCI).
Methods: We searched the bibliographic databases and the references of relevant
articles, and recruited all randomized controlled trials (RCTs) investigating the efﬁ-
cacy of TAT vs conventional anti-platelet treatment (CAT) in PCI patients with
HOPR. Recruited trials were assessed for risk of bias. Clinical events including car-
diovascular death (CV death), non-fatal myocardial infarction (non-fatal MI), stent
thrombosis (ST) and bleeding were analyzed. Trial sequential analysis was performed
to estimate the strength of evidence.
Results: Eleven RCTs involving 4787 patients with HOPR were recruited, where
2529 patients were randomized into TAT arm, and the other 2258 patients were
randomized into CAT arm. During a follow-up period of 1 to 12 months, the
incidence of CV death, non-fatal MI, and ST were all signiﬁcantly lower in the
TAT arm compared with that in the CAT arm ( (0.7% vs. 1.7%, risk ratio [RR]:
0.37; 95% conﬁdence interval [CI]: 0.19 to 0.72, P¼0.004) ; (1.5% vs. 3.1%,
RR:0.57; 95% CI: 0.39 to 0.83, P¼0.004) ; and (1.2% vs. 2.7%, RR:0.44; 95% CI:
0.27 to 0.73, P¼0.001), respectively). The combined incidence of CV death, non-
fatal MI, and ST were much lower in TAT arm compared to CAT arm (2.9% vs.
7.9%, RR: 0.49; 95% CI: 0.37 to 0.65, P<0.00001). While the incidence of
bleeding was similar between the two arms (5.3% vs. 4.3%, RR: 1.05; 95% CI:
0.86 to 1.27, P¼0.65). Trial sequential analyses demonstrated signiﬁcant evidence
supporting that TAT reduced the risk of combined incidence of CV death, non-fatal
MI and ST.
Conclusions: TAT guided by the platelet function assays reduces the risk of CV
death, non-fatal MI and ST, without additional risk of bleeding.GW25-e4606
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Objectives: The aim of this study was to obtain best estimates of the efﬁcacy and
safety of cilostazol-based triple antiplatelet therapy (TAPT: aspirin, clopidogrel and
cilostazol) compared with dual antiplatelet therapy (DAPT: aspirin and clopidogrel) in
patients undergoing coronary stent implantation.C140 JACC Vol 64/16/Suppl C j October 16–1Methods: We searched the literature to identify all randomized clinical trials
examining efﬁcacy and safety of TAPT versus DAPT in patients undergoing
coronary stent implantation. Major efﬁcacy outcomes were death, non-fatal
myocardial infarction (MI), ischemic stroke and stent thrombosis (ST) and the
safety outcome was bleeding. Data were analyzed using the Review Manager 5.0.0
software.
Results: A total of 19 trials involving 7464 patients were included. TAPT and DAPT
were associated with similar rates of death, non-fatal MI, ischemic stroke and ST,
but compared with DAPT, TAPT had lower rates of target lesion revascularization
(TLR) (RR 0.67, 95% CI [0.56, 0.82], P<0.0001) and target vessel revascularization
(TVR) (RR 0.65, 95% CI [0.55, 0.77], P<0.00001), as well as less late loss of
minimal lumen diameter (Mean difference -0.14, 95% CI [-0.17, -0.11],
P<0.00001), and less binary angiographic restenosis (RR 0.54, 95% CI [0.45, 0.65],
P<0.00001). TAPT and DAPT had similar rates of bleeding, but TAPT had
signiﬁcantly higher rates of headache, palpitation, rash and gastrointestinal side-
effects.
Conclusions: Cilostazol-based TAPT compared with DAPT is associated with
improved angiographic outcomes and decreased risk of TLR and TVR but does not
reduce major cardiovascular events and is associated with an increase in minor adverse
events.GW25-e5176
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Pilot Study
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Objectives: Percutaneous coronary intervention (PCI) of bifurcation lesions is asso-
ciated with a higher risk of adverse events. Recent studies support the use of provi-
sional side branch (SB) stenting, but the risk of SB closure after main vessel (MV)
stenting remains an important concern. We sought to establish and demonstrate the
feasibility and preliminary efﬁcacy of a novel protective ballooning technique (PBT)
for SB protection and treatment during MV stenting.
Methods: The rationale of PBT for SB protection is to preposition a small balloon
(2.0/20mm) in the SB before MV stenting while the proximal makers of the
balloon and the MV stent are being aligned. During deployment of the MV stent
(14-16 atm), the uninﬂated jailed balloon under the stent struts serves to reduce
both carina and plaque shifts due to its spatial occupation in the SB ostium.
Thereafter the jailed balloon is inﬂated at 8-14 atm to dilate the ostium. After
removing the jailed balloon MV stent’s balloon is inﬂated again at 14-16 atm to
correct stent deformation or malapposition. If SB ﬂow is preserved after MV
stenting, the jailed wire will be removed from SB; otherwise it could be used as a
marker to facilitate rewiring SB, and further kissing balloon inﬂation or provi-
sional SB stenting will be performed to restore SB ﬂow. Final intravascular ul-
trasound (IVUS) examinations were selectively performed in some patients to
check the MV stent. Procedural and immediate clinical outcomes were recorded
and reviewed.
Results: This novel technique was successfully adopted in 92 patients with
99 bifurcation lesions. The majority of patients had Medina class 1, 1, 1 bifur-
cation lesions (81%). Final TIMI 3 ﬂow was achieved in 100% of MV and
98% of SB. IVUS revealed optimal deployment of MV stent after ﬁnal inﬂation
in all checked cases (n¼13). Only one patient (1%) had lesions that required
rewiring and provisional stenting of the SB. TIMI 2 ﬂow occurred in one patient
(1%). SB loss occurred in one patient (1%), who suffered a periprocedural
myocardial infarction (MI). No jailed balloon or wire was entrapped during
any PCI.
Conclusions: Provisional stenting of complex coronary bifurcation lesions using a
PBT is associated with a high procedural success rate, improved SB patency, and a
low rate of immediate cardiac events in this feasibility study; however, randomized
trial is needed to further conﬁrm its clinical beneﬁts.GW25-e5296
Safety and efﬁcacy of a new type of Ni-Ti sirolimus-eluting stent with
bioabsorbable polymer in neointimal hyperplasia inhibition
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Objectives: The ﬁrst generation drug-eluting stent (DES) was based on 316L stainless
steel and coated with a permanent polymer which will induce chronic inﬂammation
and late in-stent thrombosis. New type of Ni-Ti sirolimus-eluting stent with bio-
absorbable polymer will be the answer to these questions.
Methods: Ni-Ti sirolimus-eluting stents with bioabsorbable polymer (n ¼ 24) and
EXCELTM stents (n ¼ 24) were randomized and implanted in left anterior descending
artery (n ¼ 24) and right coronary (n ¼ 24) of 24 pigs. Coronary angiography,IVUS
and histomorphologic analysis (neointimalarea and lumen area stenosis measurement
after hematoxylin-eosin staining; electron-microscopy scan after ﬁxing with 1%
glutaraldehyde) were performed 90 days after the stents implantation.9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
